EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Integrated genomic profiling identifies predictive biomarkers for neoadjuvant therapy response in Chinese breast cancer patients

Xiao-Han Ying, Kun-Yu Zhang, Shu-Hao Jiang, Li Chen, Jun-Jie Li, Guang-Yu Liu, Ke-Da Yu, Jiong Wu, Gen-Hong Di, Yun-Yi Wang, Lei Fan, Yi-Feng Hou und 5 weitere

Cancer Letters · 2026

DOI: 10.1016/j.canlet.2026.218503 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Xiao-Han Ying und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Fudan University Shanghai Cancer Center, China; Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Sh…. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Breast Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Anti Cancer Association, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoadjuvant therapy (NAT) has emerged as a standard treatment strategy for locally advanced breast cancer (BC), yet robust biomarkers for response prediction remain elusive. Here, we established a real-world NAT cohort of 1161 Chinese BC patients, including 1145 cases with matched clinicopathological data and targeted sequencing, to systematically evaluate genomic features associated with NAT outcomes. We identified both cross-subtype and subtype-specific genomic associations with treatment response. PI3K-pathway alterations emerged as a consistent feature of resistance across subtypes, whereas mutations such as ERBB2 in HER2+ disease and MAP3K1 in triple-negative breast cancer were associated with subtype-specific response patterns. Regimen-level analyses further showed that some genomic associations were treatment-context dependent across chemotherapy-, endocrine-, anti-HER2-, and immunotherapy-containing regimens. Among patients with non-pathological complete response (non-pCR), genomic profiling further refined risk stratification for distant recurrence by revealing subtype-specific prognostic alterations, including TOP3B and SETD2. Furthermore, a machine-learning model integrating genomic and clinicopathological features showed favorable performance for NAT response prediction. Overall, our study provides a comprehensive genomic framework for response prediction and recurrence risk assessment, supporting more precise stratification and biomarker-guided treatment optimization in Asian breast cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorBreast NeoplasmsNeoadjuvant TherapyAdultFemaleHumansMiddle AgedErb-b2 Receptor Tyrosine KinasesGene Expression ProfilingGenomicsHistone-Lysine N-MethyltransferaseMachine LearningMutationPrognosisTreatment OutcomeEast Asian People

Stichwörter der Autor:innen

Breast cancerGenomicMachine learning modelNeoadjuvant therapyTreatment response prediction

Substanzen

Biomarkers, TumorErb-b2 Receptor Tyrosine KinasesERBB2 protein, humanHistone-Lysine N-MethyltransferaseSETD2 protein, human

Autor:innen und Institutionen

  • Department of Breast Surgery, Fudan University Shanghai Cancer Center, China; Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Department of Breast Surgery, Fudan University Shanghai Cancer Center, China; Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. Electronic…
  • Department of Breast Surgery, Fudan University Shanghai Cancer Center, China; Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; Precision C…

Förderung

  • Shanghai Anti Cancer Association
  • National Natural Science Foundation of China

Zitieren

APA

Ying, X. H., Zhang, K. Y., Jiang, S. H., Chen, L., Li, J. J., Liu, G. Y., Yu, K. D., Wu, J., Di, G. H., Wang, Y. Y., Fan, L., Hou, Y. F., Shao, Z. M., Zhu, X. Z., Hu, X., Chen, C., & Wang, Z. H. (2026). Integrated genomic profiling identifies predictive biomarkers for neoadjuvant therapy response in Chinese breast cancer patients. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218503

Vancouver

Ying XH, Zhang KY, Jiang SH, Chen L, Li JJ, Liu GY, et al. Integrated genomic profiling identifies predictive biomarkers for neoadjuvant therapy response in Chinese breast cancer patients. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218503

BibTeX
@article{Ying2026,
  author = {Ying, Xiao-Han and Zhang, Kun-Yu and Jiang, Shu-Hao and Chen, Li and Li, Jun-Jie and Liu, Guang-Yu and Yu, Ke-Da and Wu, Jiong and Di, Gen-Hong and Wang, Yun-Yi and Fan, Lei and Hou, Yi-Feng and Shao, Zhi-Ming and Zhu, Xiu-Zhi and Hu, Xin and Chen, Chao and Wang, Zhong-Hua},
  title = {Integrated genomic profiling identifies predictive biomarkers for neoadjuvant therapy response in Chinese breast cancer patients},
  journal = {Cancer Letters},
  year = {2026},
  doi = {10.1016/j.canlet.2026.218503}
}
Kostenlos starten →